Gossamer Bio (GOSS) Common Equity (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Common Equity of -$161.5 million for Q1 2026, down 2483.73% year-over-year from $6.8 million in Q1 2025, and down 31.54% quarter-over-quarter from -$122.8 million in Q4 2025.
Gossamer Bio (GOSS) Common Equity (2018 - 2026) Analysis & Trends
Gossamer Bio's Common Equity history runs 9 years deep, the most recent figure standing at -$161.5 million for Q1 2026.
- In Q1 2026, Common Equity fell 2483.73% year-over-year to -$161.5 million; the TTM figure through Mar 2026 stood at -$161.5 million (down 2483.73% YoY), while the FY2025 annual figure was -$122.8 million, down 516.25% from the prior year.
- Common Equity for Q1 2026 stood at -$161.5 million, down from -$122.8 million in the prior quarter.
- The five-year high for Common Equity was $104.6 million in Q3 2023, with the low at -$161.5 million in Q1 2026.
- The 5-year median for Common Equity is $12.1 million (2022), against an average of -$4.0 million.
- The sharpest annual moves came in 2023 and 2026: Common Equity soared 419.74% in 2023, then slumped 2483.73% in 2026.
- Gossamer Bio's Common Equity stood at $12.1 million in 2022, then jumped by 419.74% to $62.8 million in 2023, then slumped by 53.02% to $29.5 million in 2024, then slumped by 516.25% to -$122.8 million in 2025, then sank by 31.54% to -$161.5 million in 2026.
- Business Quant data shows GOSS's Common Equity at -$161.5 million in Q1 2026, -$122.8 million in Q4 2025, and -$82.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | -94.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -94.03 Mn |
| Mar 31, 2026 | -161.48 Mn |
| Dec 31, 2025 | -122.76 Mn |
| Sep 30, 2025 | -82.33 Mn |
| Jun 30, 2025 | -46.11 Mn |
| Mar 31, 2025 | -6.25 Mn |
| Dec 31, 2024 | 29.49 Mn |
| Sep 30, 2024 | 54.14 Mn |
| Jun 30, 2024 | 81.53 Mn |
| Mar 31, 2024 | 26.72 Mn |
| Dec 31, 2023 | 62.77 Mn |
| Sep 30, 2023 | 104.62 Mn |
| Jun 30, 2023 | -62.80 Mn |
| Mar 31, 2023 | -28.46 Mn |
| Dec 31, 2022 | 12.08 Mn |
| Sep 30, 2022 | 56.35 Mn |
| Jun 30, 2022 | -16.46 Mn |
| Mar 31, 2022 | 30.16 Mn |
| Dec 31, 2021 | 121.46 Mn |
| Sep 30, 2021 | 169.81 Mn |